POSB74 Belantamab Mafodotin as the First-in-Class Anti-BCMA Treatment for Relapsed/Refractory Multiple Myeloma: A Budget Impact and Cost-Effectiveness Analysis
Abstract
Authors
G Speranza MJ Diliberto C Fattore F Fiorentino T Prawitz A Nikolaou R Samele